Home > Boards > US Listed > Cannabis > Aphria Inc. (APHA)

Some posters seem to dismiss income from CC

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
mx10001 Member Profile
 
Followed By 36
Posts 3,447
Boards Moderated 0
Alias Born 01/31/06
160x600 placeholder
Aphria Inc. Announces Record Adult-Use Cannabis Gross Revenue in First Quarter Fiscal Year 2021 and Sixth Consecutive Quarter... PR Newswire (Canada) - 10/15/2020 8:00:00 AM
Aphria Inc. Announces Record Adult-Use Cannabis Gross Revenue in First Quarter Fiscal Year 2021 and Sixth Consecutive Quarter... PR Newswire (US) - 10/15/2020 8:00:00 AM
Aphria Inc. Announces Completion of First EU-GMP Shipment to Germany PR Newswire (Canada) - 10/7/2020 6:30:00 AM
Aphria Inc. Announces Completion of First EU-GMP Shipment to Germany PR Newswire (US) - 10/7/2020 6:30:00 AM
Aphria Inc. to Announce First Quarter Fiscal 2021 Financial Results on October 15, 2020 PR Newswire (US) - 10/2/2020 6:30:00 AM
Aphria Inc. to Announce First Quarter Fiscal 2021 Financial Results on October 15, 2020 PR Newswire (Canada) - 10/2/2020 6:30:00 AM
Cannabis Companies Committed to Quality Carve Niche in Multi-Billion-Dollar Industry NetworkNewsWire - 9/24/2020 8:45:00 AM
Aphria Inc. to Present at the 40th Annual Canaccord Genuity Global Growth Conference PR Newswire (US) - 8/12/2020 4:30:00 PM
Aphria Inc. to Present at the 40th Annual Canaccord Genuity Global Growth Conference PR Newswire (Canada) - 8/12/2020 4:30:00 PM
Aphria Inc. Announces Strategic Supply Agreement With Canndoc PR Newswire (US) - 8/4/2020 8:00:00 AM
Aphria Inc. Announces Strategic Supply Agreement With Canndoc PR Newswire (Canada) - 8/4/2020 8:00:00 AM
Aphria Inc. Announces Fourth Quarter and Fiscal Year 2020 Results PR Newswire (Canada) - 7/29/2020 8:00:00 AM
Aphria Inc. Announces Fourth Quarter and Fiscal Year 2020 Results PR Newswire (US) - 7/29/2020 8:00:00 AM
Aphria Inc. to Announce Fourth Quarter and Fiscal 2020 Financial Results on July 29, 2020 PR Newswire (Canada) - 7/21/2020 6:00:00 AM
Aphria Inc. to Announce Fourth Quarter and Fiscal 2020 Financial Results on July 29, 2020 PR Newswire (US) - 7/21/2020 6:00:00 AM
Aphria Announces Issuance of Shares in Respect of Previously Announced Settlement of Claim PR Newswire (US) - 7/6/2020 9:25:00 AM
Aphria Announces Issuance of Shares in Respect of Previously Announced Settlement of Claim PR Newswire (Canada) - 7/6/2020 9:25:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/8/2020 9:59:40 AM
Aphria Inc. Announces First Day of Trading on NASDAQ PR Newswire (US) - 6/8/2020 9:20:00 AM
Aphria Inc. Announces First Day of Trading on NASDAQ PR Newswire (Canada) - 6/8/2020 9:20:00 AM
Certification by the Exchange Approving Securities for Listing (cert) Edgar (US Regulatory) - 6/5/2020 4:33:41 PM
Securities Registration (section 12(b)) (8-a12b) Edgar (US Regulatory) - 6/5/2020 4:21:32 PM
Notification Filed by a National Securities Exchange to Report the Removal From Listing and Registration of Matured , Redeeme... Edgar (US Regulatory) - 6/5/2020 4:17:13 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/5/2020 4:08:02 PM
Aphria Inc. to Present at the Stifel 2020 Virtual Cross Sector Insight Conference PR Newswire (US) - 6/5/2020 7:00:00 AM
mx10001   Thursday, 01/09/20 05:46:05 PM
Re: None
Post # of 14578 
Some posters seem to dismiss income from CC Pharma because it is primarily a distributor of pharmaceuticals AT THIS TIME. It is a distinction without a difference. Aphira's plan is to use CC to distribute it's MJ products throughout Germany and the the rest of the EU, as more and more countries legalize medical marijuana. The income generated by CC Pharma will remain a substantial portion of APHA's revenues and profits for years to come. It was one of the best investments made by any MJ company in the past 2 years.

Aphria Completes Acquisition of CC Pharma, Leading German Pharmaceutical and Medical Cannabis Distributor

Jan 09, 2019, 03:00 ET

LEAMINGTON, ON, Jan. 9, 2019 /PRNewswire/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APHA andNYSE: APHA) today announced that it had completed its previously announced acquisition of CC Pharma GmbH ("CC Pharma"), a leading distributor of pharmaceutical products, including medical cannabis, to more than 13,000 pharmacies in Germany, as well as throughout Europe. The Company continues to strengthen its end-to-end cannabis operations and infrastructure in Germany.

"As one of the most promising medical cannabis markets in the world, Germany is a top strategic priority for Aphria. With today's acquisition of CC Pharma, Aphria is creating a German and ultimately pan-European platform that brings together demand, supply and distribution." said Vic Neufeld, CEO of Aphria. "We're excited to welcome the CC Pharma team and the pharmacists they serve to the Aphria family."

Dr. Manfred Ziegler, Managing Director of CC Pharma, added, "We're thrilled to be joining forces with Aphria. Access to Aphria's innovative products creates significant opportunities for CC Pharma's customers to experience more medical cannabis treatment options."

CC Pharma is a leading importer and distributor of EU-pharmaceuticals for the German market. Founded in 1999, today it has over 230 employees and offices in Germany, Denmark, Poland and the Czech Republic. CC Pharma holds 318 active German national pharmaceutical licenses and 692 active EU pharmaceutical licenses, and also operates a production, repackaging and labeling facility at its headquarters in Densborn, Germany. During 2018, CC Pharma generated revenue of approximately €262 million, with EBITDA of approximately €10.5 million.

"Through a series of deliberate and strategic partnerships, investments and appointments over the past 18 months, Aphria is a front runner in the German medical cannabis market," said Hendrik Knopp, Managing Director of Aphria Germany. "CC Pharma's shared values, deep relationships and local regulatory and logistical experience are a perfect complement to Aphria's expertise. One of our first steps will be to create a new division of CC Pharma dedicated to medical cannabis."

In addition to today's acquisition of CC Pharma, other previously announced strategic milestones for Aphria and its wholly owned subsidiaries in Germany include:

A significant supply agreement to provide CC Pharma approximately 1,200 kilograms of medical cannabis products, exported from Canada and Denmark to Germany.

A 2018 investment in Berlin-based Schöneberg Hospital, a first step in Aphria's plans to build and operate pain treatment centres throughout Germany.

The construction of a state-of-the-art, GMP certified cannabis vaults (5,000 kg storage capacity), in Bad Bramstedt, Germany, to be completed by late spring 2019.

The start of construction of a Research and Development indoor growing facility in Neumünster, Germany, in preparation for in-country cultivation.

Aphria paid €18.92 million in cash to the former shareholders of CC Pharma with an earn-out multiple on future EBITDA of up to another €23.5 million, if certain performance milestones are met.

We Have A Good Thing Growing

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences